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Abstract
Introduction
Prostate cancer is one of the most prevalent cancers among men. An increase of 35,126 new cases is ex-
pected by 2020 in Spain alone. The aim of this review is to study the relationship between obesity and the 
prognosis of prostate cancer, which is playing an increasingly important role in our health system. 
A systematic search in several databases (MEDLINE, Web of Science core collection and SCOPUS) was 
conducted. This search included only observational studies (cohort and case-control studies) from 2015 to 
data extracted are the Hazard Ratio. 
Results
this review and their Hazard Ratio was analyzed. A positive association was obtained in 5 studies for a 
BMI>27.5 kg/m2 and BMI<22.5 kg/m2. Paradoxically, one associated a protective association for a BMI<25 
kg/m2. 
Conclusion
The literature reviewed indicates that obesity appears to be a bad prognostic factor in prostate cancer. 
Keywords: 
1. Introduction
Prostate cancer (PC) is one of the most common 
cancers among men. According to data from the 
Spanish Society of Medical Oncology (SEOM, by its 
Spanish acronym), PC was the second most diagno-
to its prevalence, it is (along with other cancers) a 
public health problem. In terms of mortality, PC 
is the third in Spain, after lung and colorectal can-
cer. Despite this, it has a 5-year age-adjusted sur-
data from the Spanish Network of Cancer Registry 
-
phological parameters of the tumor, histological 
type, location, perineural invasion, lymphovascular 
invasion, DNA ploidy, cell proliferation rate, p53 
mutation, BCL2 gene, p27 gene, COX-2 overexpres-
sion, factor B and E-cadherin and whether it has an 
androgen receptor or not. (3). All these variables are 
-
tors, tobacco and alcohol, infectious diseases, hor-
monal stimulation, ethnicity and obesity (4). Obe-
sity is beginning to play an increasingly important 
role in the development and prognosis of PC. When 
relating obesity to its etiological role, there does not 
-
re with the risk of suffering PC (5). Its relationship 
with prognosis, however, is more doubtful. (6). No-
netheless, the body mass index (BMI), abdominal 
circumference and weight, which are markers of 
obesity, are used to decide on treatment and predict 
its response (7).
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hip between obesity and life expectancy of PC. For 
this purpose, BMI is taken as a marker of obesity 
marker of life expectancy to further investigate this 
association, raise new hypotheses, and open new 
lines of study.
This review was conducted following PRISMA 
following key words: 1) related to PC (‘prostate 
neoplasia’, ‘prostate cancer’, and ‘malignant pros-
tate hyperplasia’), 2) combined with terms related 
to obesity (‘obesity’, ‘abdominal obesity’, ‘morbid 
obesity’, ‘body mass index’, and ‘weight’), 3) terms 
related to mortality (‘mortality’, ‘cause of death’, 
‘survival rate’, and ‘quality of life’), 4) those rela-
ted with prostate cancer recurrence were discarded 
(‘recurrence’, ‘repetition’, and ‘biochemical recu-
rrence’). This search was performed in three diffe-
rent databases (MEDLINE, Web of Science Core 
Collection, and SCOPUS).
Only those articles from January 2015 to February 
2020 were included, taking into account that they 
were original observational cohort and case/con-
trol articles, carried out in humans, and written in 
Spanish and/or English. A general review of titles 
and abstracts was then conducted by both authors 
(P.O. and J.J.P.). The exclusion criteria were: 1) ar-
ticles dealing with crude death rate of PC and not 
with net death rate (PCSM), 2) that did not use BMI 
as marker of obesity, 3) in which weight loss was 
part of PC treatment, 4) in which only crude death 
rate was considered, 5) that considered obesity as 
a risk factor for the disease, 6) in which ill patients 
were compared to healthy patients, 7) that were ei-
ther meta-analysis or reviews that resembled this 
one.
2.1. Data extraction 
Using a standardized form made by the two au-
thors (P.O. and J.J.P.), data were extracted from t: 1) 
the title, 2) year, 3) study population, 4) sample size, 
5) follow-up period, 6) mortality data and BMI (kg/
m2 -
bles. Relative risk (RR), odds ratio (OR), and hazard 
-
terval (CI) were extracted.
3. Results
After the application of the previous method, 61 
potentially useful articles were obtained. Of tho-
se, 40 were discarded since they were previous to 
2015. Next, full texts were analyzed thoroughly, 
articles (Figure 1) were selected: 7 were prospective 
cohort studies (9-15), and 1 was a retrospective co-
hort study (16) (Table 1).
Only relevant results from the relationship between 
PCSM and obesity were included. The study by Mo-
ller et al. (14) considered as a control value BMI<20 
kg/m2 (HR 1. Category 1 (C1) included men with 
PC whose BMI was between 20 and 30 kg/m2 in 
-
-
tegory 2 (C2) included men who had BMI>30 kg/
m2 with HR: 1.43 (95%CI 1.01-2.91) and aHR: 1.27 
three categories according to BMI: 1) patients with 
PC and BMI<25 kg/m2 were used as control value, 
2) C1 included those with BMI between 25-30 kg/
m2
included those with BMI>30 kg/m2 whose results 
(95%CI: 0.63-1.50). Vidal et al. (13) grouped patients 
into four different categories according to BMI: low 
weight for patients with BMI<21 kg/m2, being their 
HR:1.19 (95%CI: 0.71-1.97) and aHR: 1.14 (95%CI: 
0.67-1.95); normal weight for patients who had BMI 
values between 21-24.9 kg/m2, which was taken 
as a control value; overweight for those who had 
BMI values between 25-29.9 kg/m2 with HR:1.20 
(95%CI: 0.95-1.53) and aHR:1.17 (95%CI: 0.92-1.50); 
and obese for those with BMI>30 kg/m2 with HR: 
1.43).
Fowke et al. (10) divided patients into three groups: 
C1 included men with PC with BMI>25 kg/m2, ob-
BMI between 22.5-24.9 kg/m2 (HR 1) were used 
as control value); C2 included those with BMI be-
tween 20-22.4 kg/m2, with HR: 0.92 (95%CI: 0.75-
1.13); and C3 included those with BMI<19.9 kg/m2, 
-
cant association between obesity and PCSM, except 
Moller et al. (14), in which it did exist for patients 
with BMI>30 kg/m2, although it was the non-ad-
justed value.
Cantarutti et al. (11) used as control value BMI be-
tween 22.5-25 kg/m2 (HR 1), C1 included patients 
with BMI<22.5 kg/m2 whose results were HR: 1.33 
(95%CI: 1.02-1.74) and aHR: 1.31 (95%CI: 1.00-1.72); 
C2 included those with BMI 25<27.5 kg/m2 with HR: 
1.29); and C3 included those with BMI >27.5 kg/m2 
whose results were HR: 1.17 (95%CI: 0.96-1.43) and 
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-
tion for C3 subjects were observed (Figure 2).
Wang et al. (12) obtained the following results: sam-
ple population of 1,442 patients with localized PC, 
2
25-29.9 kg/m2; 326 BMI between 30-34.9 kg/m2; 92 
BMI 35-39.9kg/m2, and 52 BMI>40 kg/m2. PCSM at 
-
ciation between the increase in the BMI and PCSM 
(HR: 1.15. 95%CI: 1.07-1.23) was also found when 
analyzing the data with a multivariate analysis.
The study population in the study by Pérez-Cornago 
931 of the recorded deaths were PC-related and a 
positive association with BMI was found (HR: 1.14 
95%CI: 1.02-1.27). Mohammed et al. (16) obtained a 
sample of 71 patients with PC metastasis which were 
2 
(N31)) and group 2 (BMI >25 kg/m2 (N40)). In the 
When associating BMI<25 kg/m2 with PCSM, aHR 
= 0.17 (95%CI: 0.04–0.70) was analyzed, showing a 
protective association for this group.
4. Discussion
A range of possible answers have been found in the 
analyzed studies, some of which are contradictory. 
In some cases, the high BMI at the time of diagno-
sis and the increase in BMI during the disease is re-
lated to a higher PCSM (9, 11-12, 15). In contrast, 
other shows a protective association between these 
two variables (16). 
Regarding the relation between BMI increase and 
affected by other variables of obesity such as ab-
LDL, adiponectin) or height. Some of them seem to 
height. Perez-Cornago et al. (15) associated a tall 
person with a normal BMI and high adipose tissue 
mass with a higher risk of PCSM. However, the 
inverse relation between height and BMI does not 
mean that tall people with a lower BMI have lower 
levels of adiposity. These data may lead to a false 
association between BMI and PCSM (9, 14). Yang et 
PCSM. Nevertheless, when comparing this study 
with a higher risk of aggressivity, progression and 
PCSM was observed. This revealed that obese men 
have a higher probability of suffering a more ag-
gressive and higher relapse risk PC.
(12) also showed a positive association between BMI 
and relapse risk; PCSM; death rate and metastasis 
suffered by PC patients treated with radiotherapy. 
Reference is made to a multivariate analysis of age, 
androgen deprivation therapy and PSA pre-treat-
ment as a log-transformed variable. Applying all 
these variables at the same time could lead to con-
fusion. Therefore, data should be analyzed separa-
tely to avoid potential bias. Consequently, a new 
study model is needed, which takes into account 
BMI of the sample and the type of treatment depen-
ding on the patient and PC stage to determine the 
mechanisms involved in obesity and PCSM, and to 
determine whether or not an association exists and, 
if that is the case, what type.
Cantarutti et al. (11) found a correlation between 
a high PCSM and high BMI as compared to a nor-
mal BMI at the time of diagnosis. Their results also 
showed that a lower BMI also implied a higher 
PCSM although, in those cases, mortality from 
other causes also increased. These data are in line 
with those collected in the literature (19, 20). They 
suggest that different BMI ranges need to be further 
explored, i.e., to assess both the low and high ran-
ges and their relationship to PCSM.
The study by Vidal et al. (13)showed that BMI is 
not associated with an increase in PCSM. However, 
when comparing these results with those of Hala-
bi et al. (21), it they concluded that there is a pro-
tective factor between high BMI and PCSM. Two 
theories can explain this protective role. On the one 
hand, a higher BMI means less cachexia, in addi-
tion to providing protection against possible future 
cachexia (which would increase life expectancy of 
PC patients). On the other hand, obese men have 
increased estrogen formation caused by adipose tis-
sue, and this hormone in turn inhibits the growth 
of PC (22). This idea is supported by Greenlee et al. 
(23), who compiled 22 clinical trials on the associa-
tion between BMI and mortality of different types 
of cancer with their treatments. No association was 
found between BMI and the mortality of any type 
cases of PC treated with androgen deprivation the-
acted as a protective factor in relation to PCSM. 
These results shed new light on the protective role 
of adipose tissue and its endocrine function.
Regarding this protective role, the study by Dicker-
man et al. (24) on the association between visceral 
fat and advanced and fatal disease is also worth 
mentioning. They described that this association 
patients with a BMI <27 kg/m2 and weaker and 
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2. 
However, the CIs obtained, as well as evidence for 
-
cant. This casts doubt on the validity of the results.
Also relevant is the study by Langlais et al. (25)on 
diagnosis in the erroneous staging of the tumor. 
This error may lie in making the diagnosis, since the 
tests carried out might be misinterpreted due to the 
patient’s obesity. This can lead to erroneous thera-
py and therefore, a worse prognosis of the disease. 
Finally, the study Dickerman et al. (26) analyzed the 
increase in BMI from age 21to the time of PC diag-
nosis and found no association. . This means that 
-
this association, a pre-determined age range closer 
to the age of risk for PC should be studied.
A broader research should be conducted, conside-
ring grey literature, clinical trials with subgroup 
analysis working on mortality/survival based on 
BMI, and the possible existence of unpublished 
work. In addition, the range of years in the litera-
ture search should be extended, and other markers 
of obesity should be included to better assess the 
effect on prognosis of PCSM (16). 
No statistical, sensitivity or validity analysis of the 
studies have been performed during the screening 
and selection process, as well as quality assessment 
of the studies in a systematic manner by the authors 
independently. Nor was an analysis performed ac-
cording to the patient time included in the studies 
or the stage-aggressiveness of the PC they suffer.
5. Conclusion
The current literature seems to indicate that obesity 
is a poor prognostic factor in PC but there is not 
enough evidence to support this. Consequently, 
-
logies are needed as the detrimental effect of obe-
sity in this type of cancer is still unclear. It would 
be convenient to consider other markers of obesi-
ty apart from BMI (HDL, LDL and adiponectin) to 
these markers independently or jointly in the prog-
nosis of PC. 
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